Cargando…

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)

Detalles Bibliográficos
Autor principal:	Ryu, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732789/ https://www.ncbi.nlm.nih.gov/pubmed/36474349 http://dx.doi.org/10.1177/10760296221144044

Ejemplares similares

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)

Invictus
Publicado: (2010)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
por: Porter, Kim Maria Frances, et al.
Publicado: (2021)

Treatment with the direct oral anticoagulants (DOACs) Apixaban and Rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
por: Porter, Kim, et al.
Publicado: (2021)

Assessment of DOAC in GEriatrics ( Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
por: Foulon-Pinto, Geoffrey, et al.
Publicado: (2023)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
por: Anis, Takla R, et al.
Publicado: (2021)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Process evaluation of the Invictus Pathways Program
por: Post, Dannielle, et al.
Publicado: (2023)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing
por: Kampouraki, Emmanouela, et al.
Publicado: (2020)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Practical Nomogram Predicting Apixaban or Rivaroxaban Concentrations from Low-Molecular-Weight Heparin Anti-Xa Values: Special Interest in Acute Ischemic Stroke Patients
por: Brakta, Charlyne, et al.
Publicado: (2023)

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
por: McHorney, Colleen A., et al.
Publicado: (2018)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

A Longitudinal Examination of Military Veterans’ Invictus Games Stress Experiences
por: Roberts, Gareth A., et al.
Publicado: (2019)

Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
por: Sohma, Ryoichi, et al.
Publicado: (2023)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
por: Villines, Todd C, et al.
Publicado: (2019)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0atam8ob4gvenor4edab5u5jsm